trifluoperazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2740 117-89-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trifluoperazine
  • trifluoperazin
  • trifluoromethylperazine
  • trifluoroperazine
  • trifluperazine
  • triflurin
  • triperazine
  • trifluoperazine hydrochloride
  • trifluoperazine dihydrochloride
  • trifluoperazine HCl
  • flupazine
A phenothiazine with actions similar to CHLORPROMAZINE. It is used as an antipsychotic and an antiemetic.
  • Molecular weight: 407.50
  • Formula: C21H24F3N3S
  • CLOGP: 4.89
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 9.72
  • ALOGS: -4.67
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O
8 mg P
20 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 95 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.153 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.334 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 13.677 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 30.903 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 1.110 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 2.940 % High 1
herg hERG pIC50 5.979 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 14.791 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 44.259 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 0.850 % High 1
kinase-safety-class ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK 36
kinase-selectivity-class AXL,PDK4 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.297 High 1
mh-clint Mouse hepatocyte intrinsic clearance 95.499 High 1
mppb Mouse plasma protein binding (% unbound) 1.100 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 5.176 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1
pppb Pig plasma protein binding (% unbound) 3.020 % High 1
rh-clint Rat hepatocyte intrinsic clearance 201.372 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 4.240 % High 1
rppb Rat plasma protein binding (% unbound) 1 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 41.687 uM High 1

Approvals:

DateAgencyCompanyOrphan
April 16, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 99.76 54.14 32 567 82315 90545533
Persecutory delusion 64.20 54.14 12 587 3196 90624652

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antipsychotic drug level below therapeutic 638.96 232.23 115 2120 3089 42616011
Disinhibition 616.54 232.23 115 2120 3780 42615320
Therapeutic product effect variable 616.05 232.23 111 2124 2998 42616102
Obsessive-compulsive disorder 576.99 232.23 119 2116 6624 42612476
Euphoric mood 564.50 232.23 116 2119 6337 42612763
Increased appetite 521.68 232.23 115 2120 8791 42610309
Akathisia 503.36 232.23 115 2120 10336 42608764
Suicide attempt 362.08 232.23 122 2113 45978 42573122
Leukaemia 306.98 232.23 69 2166 5703 42613397
Therapeutic product effect incomplete 272.28 232.23 111 2124 70828 42548272
Weight increased 242.73 232.23 116 2119 107867 42511233
Leukopenia 236.53 232.23 102 2133 74644 42544456

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antipsychotic drug level below therapeutic 275.92 74.00 43 1627 1692 110585937
Therapeutic product effect variable 256.63 74.00 43 1627 2675 110584954
Disinhibition 250.52 74.00 43 1627 3091 110584538
Euphoric mood 241.30 74.00 49 1621 8778 110578851
Obsessive-compulsive disorder 220.58 74.00 44 1626 7197 110580432
Akathisia 208.98 74.00 49 1621 17064 110570565
Increased appetite 183.43 74.00 43 1627 14934 110572695
Dyslipidaemia 180.70 74.00 43 1627 15922 110571707
Suicide attempt 161.53 74.00 60 1610 103334 110484295
Schizoaffective disorder 157.40 74.00 29 1641 3107 110584522
Irritability 138.13 74.00 44 1626 47765 110539864
Leukaemia 110.16 74.00 25 1645 7493 110580136
Leukopenia 98.76 74.00 47 1623 148744 110438885
Prescribed overdose 98.15 74.00 40 1630 87541 110500088
Obesity 97.85 74.00 43 1627 113308 110474321

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AB06 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperazine structure
FDA CS M0016525 Phenothiazines
MeSH PA D000932 Antiemetics
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014150 Antipsychotic Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018492 Dopamine Antagonists
FDA EPC N0000175746 Phenothiazine
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drug
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
CHEBI has role CHEBI:86385 EC 5.3.3.5 (cholestenol Δ-isomerase) inhibitor
CHEBI has role CHEBI:130181 calmodulin antagonist

Related Drugs by ATC class:

N05AB Phenothiazines with piperazine structure 9 drugs
acetophenazinebutaperazinedixyrazinefluphenazineperazineperphenazineprochlorperazinethiopropazatethioproperazine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002
Schizophrenia indication 58214004 DOID:5419
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Cirrhosis of liver contraindication 19943007 DOID:5082
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Retinal disorder contraindication 29555009 DOID:5679
Alcoholic liver damage contraindication 41309000
Low blood pressure contraindication 45007003
Chronic hepatitis contraindication 76783007 DOID:2237
Epilepsy contraindication 84757009 DOID:1826
Tardive dyskinesia contraindication 102449007
Diminished sweating contraindication 111980002
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.74 Basic
pKa2 4.74 Basic
pKa3 2.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.84 PDSP CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.19 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.82 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.29 DRUG MATRIX
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 8.10 CHEMBL
Multidrug resistance protein 1 Transporter Ki 5.19 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.02 PDSP
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.90 IUPHAR
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 6.40 IUPHAR
5-hydroxytryptamine receptor 6 GPCR Ki 6.85 PDSP
5-hydroxytryptamine receptor 7 GPCR Ki 6.54 PDSP
Alpha-1A adrenergic receptor GPCR Ki 7.62 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.79 PDSP
D(3) dopamine receptor GPCR ANTAGONIST Ki 9.25 PDSP
Histamine H1 receptor GPCR ANTAGONIST Ki 7.20 IUPHAR
Muscarinic acetylcholine receptor M3 GPCR Ki 6 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.41 PDSP
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.38 PDSP
Calmodulin Cytosolic other Kd 6 CHEMBL
DNA-dependent protein kinase catalytic subunit Kinase IC50 4 CHEMBL
Emopamil-binding protein-like Enzyme Ki 8.41 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.30 CHEMBL
Trypanothione reductase Enzyme Ki 4.64 CHEMBL
D(2) dopamine receptor GPCR Kd 9.27 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.39 CHEMBL
NS3 Enzyme IC50 6.15 CHEMBL
Beta-glucuronidase Enzyme IC50 5.11 CHEMBL
Lysozyme C-1 Enzyme IC50 5.05 CHEMBL
C-8 sterol isomerase Enzyme Ki 6.30 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.85 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.53 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Kd 8.98 CHEMBL
Calmodulin Cytosolic other Kd 5.47 CHEMBL
Genome polyprotein Polyprotein IC50 6.16 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme IC50 4.35 CHEMBL

External reference:

IDSource
4019957 VUID
N0000148042 NUI
D00799 KEGG_DRUG
440-17-5 SECONDARY_CAS_RN
4018843 VANDF
4019957 VANDF
C0040979 UMLSCUI
CHEBI:45951 CHEBI
CHEMBL422 ChEMBL_ID
CHEMBL1257040 ChEMBL_ID
D014268 MESH_DESCRIPTOR_UI
DB00831 DRUGBANK_ID
5566 PUBCHEM_CID
214 IUPHAR_LIGAND_ID
718 INN_ID
214IZI85K3 UNII
10800 RXNORM
2926 MMSL
5625 MMSL
d00890 MMSL
001481 NDDF
004590 NDDF
373524005 SNOMEDCT_US
50754002 SNOMEDCT_US
71699007 SNOMEDCT_US
TFP PDB_CHEM_ID
214IZI85K3 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2401 TABLET, FILM COATED 1 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2402 TABLET, FILM COATED 2 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2405 TABLET, FILM COATED 5 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2410 TABLET, FILM COATED 10 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8028 TABLET, FILM COATED 1 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8032 TABLET, FILM COATED 2 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8034 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8036 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
TRIFLUOPERAZINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-305 TABLET, FILM COATED 2 mg ORAL ANDA 11 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 48433-140 TABLET, FILM COATED 1 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 48433-141 TABLET, FILM COATED 2 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 48433-142 TABLET, FILM COATED 5 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 48433-143 TABLET, FILM COATED 10 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-572 TABLET, FILM COATED 1 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-573 TABLET, FILM COATED 2 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-574 TABLET, FILM COATED 5 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-575 TABLET, FILM COATED 10 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0629 TABLET, FILM COATED 2 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0819 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-2095 TABLET, FILM COATED 2 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-2106 TABLET, FILM COATED 5 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-4554 TABLET, FILM COATED 2 mg ORAL ANDA 14 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-4686 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72162-2204 TABLET, FILM COATED 1 mg ORAL ANDA 14 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72162-2205 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72162-2206 TABLET, FILM COATED 2 mg ORAL ANDA 14 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72162-2207 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections